Thornhill, Canada Clinical Trials

A listing of Thornhill, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 226 clinical trials
Featured trial
Sickle Cell Disease Study: Own Your Health, Share Your Story with PicnicHealth

Get all of your medical records in one secure account and contribute to important real-world Sickle Cell research with PicnicHealth. If you have Sickle Cell, you get $50 for signing up and a free lifetime access to your medical records.   Visit this link to learn more and sign up. …

Online studies
PicnicHealth
(online study) Contact site
  • 11 views
  • 04 Aug, 2022
  • 1 location
  • Online study
Featured trial
INCB 18424-303: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE-AD1)

A Phase 3, randomized (2:2:1), double-blind, 8-week vehicle control efficacy and safety study of ruxolitinib followed by a randomized, double-blind, 44-week long term safety (LTS) extension period.  In the LTS period,  participants initially randomized to vehicle will receive either ruxolitinib 0.75% or 1.5% cream.  All participants will have follow-up assessments …

atopic dermatitis/eczema
eczema
atopic dermatitis
YORK DERMATOLOGY CENTER
 (4.2 away) Contact site
  • 582 views
  • 10 May, 2022
  • +18 other locations
Featured trial
Integument-2 study

We are currently recruiting pediatric and adult patients with mild to moderate atopic dermatitis (eczema) for a study that investigates the safety and efficacy of the ARQ-151 cream.

Research Toronto
 (10.0 away) Contact site
  • 68 views
  • 07 Jul, 2022
  • +62 other locations
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada  

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.   This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept …

epoetin alfa
Sunnybrook Health Sciences Centre
 (7.2 away)
  • 23119 views
  • 01 Jul, 2022
  • +9 other locations
Objective, Passive Assessment of LRRK2 Carriers (OPAL)

This study is currently only open to active participants in the University of Rochester’s VALOR-PD study. The goal of this project is to identify objective, sensitive, and convenient measures for assessing early signs of Parkinson's disease in an at-risk population at home. We will do so by using a wireless …

Online studies
movement disorder
University of Rochester
(online study) Contact site
  • 8 views
  • 12 May, 2022
  • 1 location
  • Online study
Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection (TAPER-V)

The first line therapy for an initial episode of CDI (Clostridium difficile infection) is 10-14 days of oral vancomycin which is now recommended over metronidazole in the 2018 guidelines from the Association of Medical Microbiologists and Infectious Diseases of Canada (AMMI). Although response rates for the treatment of a first …

Sunnybrook Health Science Centre
 (7.2 away) Contact site
  • 0 views
  • 19 Apr, 2022
  • +2 other locations
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

This is a prospective Phase II multi-center study with an upfront 16-week, randomized, double-blind, placebo-controlled period, and extension periods, to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult participants with PIK3CA-related overgrowth spectrum (PROS).

Novartis Investigative Site
 (7.2 away) Contact site
  • 0 views
  • 09 Jun, 2022
  • +29 other locations
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.

Novartis Investigative Site
 (7.2 away) Contact site
  • 66 views
  • 17 Jun, 2022
  • +17 other locations
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

Sunnybrook Health Science Centre ( Site 0210)
 (7.2 away) Contact site
  • 185 views
  • 05 Jul, 2022
  • +96 other locations
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.

Canadian Phase Onward Inc
 (2.9 away) Contact site
  • 2 views
  • 09 Jul, 2022
  • +33 other locations